The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial Open Access

I.M. Browne: Conceptualization, data curation, formal analysis, investigation, writing–original draft, writing–review and editing. J. Pascual: Conceptualization, data curation, formal analysis, investigation, writing–review and editing. R.J. Cutts: Data curation, formal analysis, methodology, writing–review and editing. B. Kingston: Writing–review and editing. S. Hrebien: Data curation, writing–review and editing. L.S. Kilburn: Formal analysis, methodology, writing–review and editing. A. Pearson: Methodology, writing–review and editing. L. Moretti: Writing–review and editing. A.M. Wardley: Writing–review and editing. I.R. Macpherson: Writing–review and editing. R.D. Baird: Writing–review and editing. R. Roylance: Writing–review and editing. M.J. Gil-Gil: Validation, methodology. Á.L. Guerrero-Zotano: Validation, methodology. I. Garcia-Murillas: Methodology, writing–review and editing. J.M. Bliss: Methodology, writing–review and editing. A. Ring: Investigation, methodology, writing–review and editing. M. Martín: Validation, investigation, writing–review and editing. N.C. Turner: Conceptualization, formal analysis, supervision, visualization, methodology, writing–original draft, writing–review and editing.

The plasmaMATCH trial is funded by the Stand Up to Cancer Campaign for Cancer Research UK (CRUK/15/010 and C30746/A19505), with additional support from AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States, who are co-developing olaparib, Puma Biotechnology, Guardant Health, and Bio-Rad. Grateful thanks to all trial participants and their families. This work uses data provided by patients and collected by the NHS as part of their care and support. We thank Breast Cancer Now for funding this work as part of Program Funding to The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London. This study represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, London, United Kingdom. Thanks also to staff at participating centers, the ICR-CTSU trial team, the staff at central laboratories, and Dr. Syed Haider and his team in the Breast Cancer Now Toby Robins Research Centre for Breast Cancer Data Science support and we thank Breast Cancer Now for supporting the work of this team. plasmaMATCH is cosponsored by The Institute of Cancer Research and the Royal Marsden National Health Service Foundation Trust. The ICR-CTSU is supported by the Cancer Research UK core programme grant (C1491/A25351). plasmaMATCH is supported by the NIHR Manchester Clinical Research Facility at the Christie Hospital, Manchester, United Kingdom, the NIHR UCLH Clinical Research Facility at University College London Hospitals NHS Foundation Trust, London, United Kingdom, the Cancer Research UK Cambridge Centre, the Cambridge NIHR Biomedical Research Centre (BRC-1215-20014), the Cambridge Experimental Cancer Medicine Centre, Cambridge, United Kingdom, and by the Glasgow Experimental Cancer Medicine Centre, which is funded by Cancer Research UK and The Chief Scientist’s Office, Scotland (grant award A25174). plasmaMATCH is supported at participating sites in England by the NIHR Clinical Research Network, in Scotland by the Chief Scientist Office, and in Wales by Health and Care Research Wales. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The authors also acknowledge past and present colleagues on the plasmaMATCH trial management group, the IDMC, and the TSC, who provided oversight of the trial.